Full Press Release Details
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer.
IDYA
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer
Key Takeaway: IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR , Her2 , BRCA1 2 mutant Breast Cancer
Price reaction · baseline $26.42 (2023-09-26 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close
-0.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma